omega-n-methylarginine has been researched along with sulfaphenazole in 7 studies
| Studies (omega-n-methylarginine) | Trials (omega-n-methylarginine) | Recent Studies (post-2010) (omega-n-methylarginine) | Studies (sulfaphenazole) | Trials (sulfaphenazole) | Recent Studies (post-2010) (sulfaphenazole) |
|---|---|---|---|---|---|
| 4,411 | 344 | 336 | 365 | 8 | 96 |
| Protein | Taxonomy | omega-n-methylarginine (IC50) | sulfaphenazole (IC50) |
|---|---|---|---|
| Cytochrome P450 2C9 | Homo sapiens (human) | 1.3731 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Büssemaker, E; Fauler, J; Fleming, I; Gross, P; Lässig, G; Passauer, J; Pistrosch, F | 1 |
| Breuer, S; Busse, R; Dimmeler, S; Fichtlscherer, S; Fleming, I; Zeiher, AM | 1 |
| Büssemaker, E; Fleming, I; Gross, P; Herbrig, K; Lässig, G; Passauer, J; Pistrosch, F | 1 |
| Cipriano, A; Franzoni, F; Galetta, F; Ghiadoni, L; Magagna, A; Salvetti, A; Taddei, S; Versari, D; Virdis, A | 1 |
| Donato, AJ; Eskurza, I; Gano, LB; Jablonski, KL; Pierce, GL; Seals, DR | 1 |
| De Negri, F; Duranti, E; Giannarelli, C; Magagna, A; Salvetti, A; Taddei, S; Virdis, A | 1 |
| Ambrogini, E; Banti, C; Bernini, G; Carrara, D; Cetani, F; Ghiadoni, L; Giannarelli, C; Marcocci, C; Pinchera, A; Taddei, S; Virdis, A | 1 |
2 trial(s) available for omega-n-methylarginine and sulfaphenazole
| Article | Year |
|---|---|
Baseline blood flow and bradykinin-induced vasodilator responses in the human forearm are insensitive to the cytochrome P450 2C9 (CYP2C9) inhibitor sulphaphenazole.
Topics: Adult; Analysis of Variance; Aryl Hydrocarbon Hydroxylases; Bradykinin; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C9; Forearm; Humans; Ibuprofen; Male; Nitric Oxide Synthase; omega-N-Methylarginine; Plethysmography; Regional Blood Flow; Sulfaphenazole; Vasodilator Agents | 2003 |
Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease.
Topics: Acetylcholine; Adult; Aryl Hydrocarbon Hydroxylases; Ascorbic Acid; Blood Proteins; Coronary Artery Disease; Cytochrome P-450 CYP2C9; Endothelium, Vascular; Enzyme Inhibitors; Forearm; Humans; Male; Middle Aged; Nitric Oxide; omega-N-Methylarginine; Oxidation-Reduction; Regional Blood Flow; Sulfaphenazole; Vasodilation; Vasodilator Agents | 2004 |
5 other study(ies) available for omega-n-methylarginine and sulfaphenazole
| Article | Year |
|---|---|
Nitric oxide- and EDHF-mediated arteriolar tone in uremia is unaffected by selective inhibition of vascular cytochrome P450 2C9.
Topics: Acetylcholine; Adult; Arterioles; Aryl Hydrocarbon Hydroxylases; Biological Factors; Case-Control Studies; Cytochrome P-450 CYP2C9; Endothelium, Vascular; Enzyme Inhibitors; Humans; Male; Nitric Oxide; Nitric Oxide Synthase; Nitroprusside; omega-N-Methylarginine; Sulfaphenazole; Uremia; Vasodilation; Vasodilator Agents | 2005 |
Identification of a cytochrome P450 2C9-derived endothelium-derived hyperpolarizing factor in essential hypertensive patients.
Topics: Acetylcholine; Adult; Aryl Hydrocarbon Hydroxylases; Ascorbic Acid; Biological Factors; Bradykinin; Case-Control Studies; Cytochrome P-450 CYP2C9; Drug Combinations; Drug Synergism; Endothelium, Vascular; Enzyme Inhibitors; Female; Forearm; Humans; Hypertension; Male; Microcirculation; Middle Aged; Nitroprusside; omega-N-Methylarginine; Regional Blood Flow; Sulfaphenazole; Vasodilation; Vasodilator Agents | 2006 |
Cytochrome P-450 2C9 signaling does not contribute to age-associated vascular endothelial dysfunction in humans.
Topics: Acetylcholine; Adult; Age Factors; Aged; Aging; Aryl Hydrocarbon Hydroxylases; Brachial Artery; Cytochrome P-450 CYP2C9; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme Inhibitors; Female; Forearm; Humans; Male; Middle Aged; Nitric Oxide; Nitric Oxide Synthase; Nitroprusside; omega-N-Methylarginine; Oxidative Stress; Regional Blood Flow; Signal Transduction; Sulfaphenazole; Vasodilation; Vasodilator Agents | 2008 |
Effect of sulfaphenazole on tissue plasminogen activator release in normotensive subjects and hypertensive patients.
Topics: Acetylcholine; Adult; Aryl Hydrocarbon Hydroxylases; Blood Pressure; Bradykinin; Case-Control Studies; Cytochrome P-450 CYP2C9; Endothelium, Vascular; Female; Forearm; Humans; Hypertension; Male; Microcirculation; Middle Aged; omega-N-Methylarginine; Sulfaphenazole; Tissue Plasminogen Activator | 2009 |
The sulfaphenazole-sensitive pathway acts as a compensatory mechanism for impaired nitric oxide availability in patients with primary hyperparathyroidism. Effect of surgical treatment.
Topics: Adult; Aged; Aryl Hydrocarbon Hydroxylases; Ascorbic Acid; Biological Factors; Cytochrome P-450 CYP2C9; Endothelium, Vascular; Female; Humans; Hyperparathyroidism, Primary; Middle Aged; Nitric Oxide; omega-N-Methylarginine; Parathyroidectomy; Sulfaphenazole; Vasodilation | 2010 |